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Current diagnostics of dry eye disease are unable to identify the multiple complex causes 
of dry eye, thereby limiting the proper treatments of the disease. The tear glycoprotein lacritin 
has been reported to be decreased in dry eye patients, specifically those with Sjӧgren’s syndrome 
associated dry eye. Therefore, the use of lacritin in a diagnostic test for dry eye could improve 
the current diagnostics available. Western blot assays have revealed the presence of an active 
lacritin monomer as well as an inactive tissue transglutaminase cross-linked polymer in human 
tears.  A third isoform of lacritin, the splice variant lacritin-c, has also been detected in human 
tears. Using a diagnostic multiplex western blot assay, the three lacritin isoforms were 
quantitated in forty samples of human tears from twenty adults and analyzed using JMP 
software. This provided a baseline distribution of percent lacritin in human tears that will be used 
in future lacritin clinical trials. 
INTRODUCTION 
One of the most common problems in ophthalmology is dry eye disease; however, diagnosis 
is difficult due to multiple causes of the disease and lack of a definitive diagnostic test. 
Currently, there is no consensus on the guidelines for diagnosis, and the causes of dry eye are 
complex, ranging from premenopausal symptoms in women to altered corneal innervation 
(McNamara et al., 2016). Dry eye consists of a wide spectrum of dysfunctions and there is no 
specific separation between an eye designated as “normal” and an eye that presents dry eye.  
Additionally, the current diagnostic tests for dry eye are not standardized, making comparison 
between patients difficult (Savini, 2008). The most commonly used diagnostic tool for dry eye 
diagnosis is the Schirmer tear test (STT) which measures total tear secretion by inserting 




production (Boyd, 2018). After five minutes, the strip is removed, and wetting is recorded in 
millimeters (mm). Normal tears are diagnosed by wetting over 10mm, and dry eye tears are 
diagnosed by wetting less than 10mm. Unfortunately, there are multiple issues with using the 
Schirmer tear test that include low reproducibility, sensitivity, frequent discomfort, difficulty 
performing tests in children, and potential injury to conjunctiva and cornea (Salomon-Ben Zeev 
et al., 2014). Due to varying diagnostics and causes for dry eye there is a need for a reproducible 
test for the disease.  
One of the emerging technologies for the diagnosis of dry eye is the use of tear biomarkers to 
analyze tear protein patterns and identify dry eye in a protein-specific manner. The tear 
glycoprotein, lacritin, has demonstrated potential as a protein biomarker for dry eye (Karnati et 
al., 2013). Lacritin is a prosecretory mitogenic protein that is known to promote basal tearing and 
exhibits cytoprotective activity (Wang et al., 2015). Structurally, lacritin has a molecular weight 
of 12.3 kDa, an isoelectric point of 5, and consists of 119 amino acids; tertiary structure of 
lacritin consists of two alpha helices, one amphipathic, and one that supports ligand-ligand 
binding (Ma et al., 2008). The lacritin gene contains 5 coding exons and 4 noncoding introns. 
The splice variant, lacritin-c, lacks exons 4 and 5 entirely and has sequences encoding 39 amino 
acids found in intron 3 (McKown et al., 2010). When cleaved, lacritin releases the amphipathic 
a-helical fragment, which creates bactericidal activity of tears by promoting metabolic stress and 
eventual bacterial death (McKown et al., 2014). 
Lacritin promotes ocular health but is seen to be downregulated in dry eye and other dry eye 
related diseases. An example of a dry eye related disease with a connection to lacritin is 
Sjӧgren’s syndrome, which has been linked to low levels of lacritin (McNamara et al., 2016).  




symptoms, and currently there is no cure for this disease. However, when lacritin is present in 
sufficient amounts for healthy individuals, the protein restores corneal homeostasis and promotes 
basal tear secretion, as well as, epithelial cell proliferation (Karnati et al., 2016),(Wang et al., 
2006). Therefore, lacritin demonstrates an inverse relationship to dry eye symptoms.  
Because of the relationship between lacritin and dry eye, lacritin in ocular disease has been 
studied to determine the use of lacritin as a potential therapeutic. In a study comparing lacritin 
treatment in rabbits with cyclosporin and artificial tears, lacritin was found to increase basal 
tearing in rabbits, while the other treatments were unable to match the same results (Samudre et 
al., 2011). Another study utilized a dry-eye treatment consisting of thermo-responsive lacritin 
combined with an elastin-like polypeptide, which increased tear secretion in mice (Wang et al., 
2015). Therefore, lacritin can promote natural tear secretion in dry eye when topically applied.  
Additionally, lacritin has demonstrated protective activities after corneal epithelia exposure to 
benzalkonium chloride (BAK), a preservative found in eye drops. BAK causes ocular surface 
inflammation and toxicity, but when lacritin is applied to corneal epithelia exposed to BAK, 
there is increased cell proliferation, suggesting the use of lacritin as a treatment for BAK 
exposure (Feng et al., 2014). This protective role of lacritin was also shown to alleviate apoptosis 
of lipopolysaccharide challenged corneal epithelial cells (Vantaku et al., 2016). These studies 
demonstrate lacritin’s potential use as a biotherapeutic, as lacritin activity targets the causes of 
dry eye rather than treating the symptoms (Karnati et al., 2013). 
Sjӧgren’s syndrome, an autoimmune disorder characterized by severe dry eye, has been 
shown to have a strong relationship with lacritin. In a previous study, SS patients and normal 
controls were assayed for lacritin proteins by western blot analysis, which revealed that 




(Vijmasi et al., 2014). In another study with SS patients, active tear lacritin was reduced in SS 
patients when compared to age matched controls, and reduced levels of lacritin were correlated 
to dry eye symptoms in SS patients (McNamara et al., 2016). Thus, the relationship between SS 
associated dry eye and lacritin suggests that the protein has potential as both a diagnostic 
biomarker and a topical therapeutic for SS dry eye. 
Herein is reported the application of a multiplex western blot assay to quantify tear lacritin 
isoforms in twenty healthy adults. These isoforms consist of monomeric lacritin, the splice 
variant lacritin-c, and a cross-linked form of lacritin formed from an inactive tissue 
transglutaminase cross-linked polymer, which negatively regulates lacritin activity (Velez V et 
al., 2013). Tear samples from twenty healthy adults were eluted and analyzed by multiplex 
western blots. This was performed in preparation for receipt of samples from the phase 2 trial of 
LacripepTM in Sjӧgren's syndrome Dry Eye and from a non-interventional study of lacritin from 
healthy volunteers. Samples from both the right (oculus dexter-OD) and left (oculus sinister-OS) 
eyes were collected from both male and female subjects of varying ages. By quantitating 
different forms of lacritin among twenty healthy subjects, we can provide a baseline for future 
analysis of tear lacritin proteins in diseases such as Sjӧgren’s syndrome. 
 
MATERIALS AND METHODS 
Collection and Elution of Tears 
Normal human tears were collected using Schirmer tear test strips that were placed in 
cryotubes and stored at -20° C at the University of California San Francisco (UCSF). All 




Committee for Human Research, as well as HIPPA laws. Informed consent was obtained from 
all subjects. 
Once the tear samples were collected, the Schirmer strips were shipped on dry ice and 
stored at -60°C until thawed for elution. For elution, sixty microliters of phosphate buffer saline 
(PBS) were loaded onto the thawed Schirmer strips placed in spin baskets inserted into 
microcentrifuge tubes. Tubes were incubated for twenty minutes at room temperature and then 
centrifuged at 13,000 rotations per minute (RPM) for an additional ten minutes at 4°C. The 
eluted products were analyzed with the Bicinchoninic Acid Assay (BCA) for determination of 
total protein concentration (µg/mL) eluted from each tear sample. 
Bicinchoninic Acid Assay (BCA) 
The Thermo Scientific Pierce BCA Protein Assay Kit was utilized to determine total 
protein concentration of each tear sample against a protein standard. Tear samples were loaded in 
duplicate into a 96 well microtiter plate along with bovine serum albumin (BSA) standards 
ranging from 0 mg/mL to 2.0 mg/mL. Samples and standards were loaded in volumes of 10uL 
and analyzed at 570 nm using a spectrophotometer, following a thirty-minute reaction with 
working reagent at 37°C. Unknown concentrations of total protein in each tear sample were 
identified in mg/mL after comparison with absorbance values and known concentrations 
generated through a BSA standard curve.  
Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis (SDS-PAGE) and Western 
Blots 
Tear samples were normalized to 400 µg/mL and loaded onto Any kD™ Mini-
PROTEAN® TGX™ Precast Protein Gels (Bio-Rad) and electrophoresed at 200 volts via 




validation, 40 tear samples were divided into 5 sets (101-104, 105-107&109, 110-113, 108&114-
116, 117-120 OD, OS) and each set was run in duplicate. Each gel was transferred to 
nitrocellulose (Protran BA 83; Whatman, Dassel, Germany) using a trans-blot apparatus run at 
100 volts for one hour (Appendix B).  Blots were stored at 4°C until probed with antibodies. 
 For development, the blots were washed for ten minutes with phosphate buffer saline 
and 0.3% tween-20 (PBS-T) for a total of four washes at ten minutes each. Blots were incubated 
with either anti-Lacritin N-term rabbit polyclonal antibodies (1:1500 dilution in PBS-T) or anti-
Lacritin I3 rabbit polyclonal antibodies (1:1500 dilution in PBS-T), developed from Bio-
Synthesis Inc (Lewisville, TX). N-term antibodies recognize all three lacritin isoforms, while I3 
antibodies recognize only the splice variant and cross-linked isoforms of lacritin. The incubation 
took place for one hour at room temperature, and blots were rinsed with PBS-T for an additional 
four washes of ten minutes each, then incubated again for one hour with fluorescently labeled 
goat anti-rabbit antibodies (1:12,500 dilution in PBS-T), followed by four washes with PBS-T at 
10 minutes each. 
Imaging and Quantitation of Lacritin Isoforms 
 Blots were imaged on a LiCor Odyssey CLx imaging system. The Odyssey CLx utilizes 
two lasers that scan the blots twice, once using each laser’s high wavelength (800nm), and 
another using each laser’s low wavelength (700nm). These scans from each laser come together 
to form one image (Bouzid, Ahmed, Lesiak, 2013). Using ImageSoftware Lite, quantitation of 
lacritin isoforms was determined based on relative signal obtained from the Odyssey CLx image. 
Using a standard curve generated from recombinant lacritin standards of known concentrations 
on each blot, nanograms (ng) of lacritin were calculated. From the nanograms of lacritin and the 




calculated. The lacritin percentages among the samples were distributed using a quartile system 
obtained from JMP software. 
 
RESULTS 
Optimization of the Multiplex Western Blot Assay 
 In this study, the multiplex western blot assay was optimized to determine the most 
efficient antibody dilutions, as well as, concentrations of both recombinant lacritin standards and 
human tear samples to be used in the western blot. The LI-COR Odyssey CLx imaging system, 
used to detect the presence of each lacritin isoform, demonstrated that primary antibody dilutions 
of 1:1500 and secondary antibody dilutions of 1:12,500, as well as, loaded samples of 400µg/mL 
displayed the most clear and distinct western bands to be used in quantitation. This allowed for 
more precise quantitation of each lacritin isoform, providing accurate identification for the 
distribution of mass and percent lacritin isoforms throughout the forty samples. 
Antibodies Detect Different Isoforms of Lacritin in Human Tears 
To detect lacritin isoforms in the multiplex western blot assay, antibodies were produced 
that would identify the monomeric, cross-linked, and splice variant isoforms. The lacritin gene 
contains five coding exons separated by four introns which produces the mature monomeric 
protein of 119 amino acids found in human tears. The splice variant, lacritin-c contains exons 2 
and 3 fused in-frame to 39 amino acids of intron 3, which produces a truncated protein of 104 
amino acids also found in human tears (unpublished data). Rabbit polyclonal antibodies were 
produced against the first 22 amino acids of exon 2 (N-Term Antibody) and 31 amino acids of 
intron 3 (I3 Antibody) (Figure 1A).  
One western blot of six tear samples and recombinant lacritin was challenged with anti-




lacritin I3 Antibody (Figure 1B and 1C). Western blots developed by fluorescent secondary 
antibodies and imaged by the LI-COR Odyssey CLx imaging system revealed the anti-lacritin N-
Term antibodies detected full length tear lacritin (monomer), recombinant lacritin, and lacritin-c 
(Figure 1B) while I3 antibodies only detected lacritin-c specific sequences (Figure 1C).  Both 
antibodies detected cross-linked forms of lacritin (Figure 1B & 1C). These antibodies were then 



























Figure 1. Antibodies Detect Different Isoforms of Lacritin in Human Tears. (A) Anti-lacritin antibodies 
were produced against N-term sequences and unique sequences of the splice variant lacritin-c. (B) N-term 
antibodies detect monomeric lacritin, cross-linked lacritin, lacritin-c in human tears and recombinant 
lacritin produced in bacteria by Western blot analysis. (C) Antibodies unique to intron 3 of lacritin (I3) 





Quantitation of Tear Lacritin Isoforms by Western Blot 
To quantify the tear lacritin isoforms on western blots, known masses of purified lacritin 
(ng) were run along with tear samples on the same blot and used to generate a standard curve. A 
western blot containing six human tear samples and the purified recombinant lacritin standards 
was probed with anti-lacritin N-Term antibodies, developed with fluorescent secondary antibodies, 
and imaged by the LI-COR Odyssey CLx imaging system (Figure 2A). The LI-COR Odyssey CLx 
imaging system produced a signal number for each band identified on the blot generated by the 
near-infrared fluorescent detection of the used secondary antibodies (Figure 2A). Near-infrared 
fluorescent detection of purified recombinant lacritin standards were plotted against the known 
masses of those same standards to generate a standard curve of signal versus lacritin (ng) (Figure 
2B). Specific protein bands for lacritin, lacritin-c, and cross-linked polymers of lacritin from 
human tears were quantified by near-infrared fluorescent signals, and a linear regression equation 
(y=1.09x) generated from recombinant lacritin was used to approximate the masses of tear lacritin 










































Figure 2. Western Blot Quantitative Analysis. (A) Human tear samples and recombinant lacritin 
challenged with anti-lacritin N-Term primary antibodies and fluorescent secondary antibodies (B) 
Decreasing concentrations of recombinant lacritin were quantified using near-infrared fluorescent detection 
and plotted against known masses of recombinant lacritin (ng) to generate a standard curve of signal versus 
lacritin (ng). (C) Specific protein bands for lacritin, lacritin-c, and cross-linked polymers of lacritin from 
human tears were quantified and a linear regression equation was used to approximate concentrations of 
tear lacritin proteins.    
 
Assay Validation with Tear Samples from 20 Adults  
In order to validate the immunoassay, tear samples from both eyes (OD and OS) of 
twenty adults were first analyzed for total eluted protein. Total protein concentration of the 
eluted samples was determined using the bicinchoninic acid assay (BCA) (Appendix A). The 
distribution of protein concentrations (Figure 3A) was divided into quartiles using JMP software 
(Figure 3B). The 25th quartile, median (50th) quartile, and 75th quartile total protein 




Figure 3. Distribution of Total Eluted Protein from 20 Adults (40 samples).  Distribution of eluted 
protein concentrations versus sample number as a scatter plot (A) and the distribution of eluted protein 
based on a quartile system (B). The standard deviation is represented to the right of the curve along with 
tick marks denoting the 5th and 95th percentiles of the curve. Additionally, the curves are divided into 
quartiles (25th, 50th, and 75th) as denoted by the box to the right of the curve. The diamond within this 
quartile box represents the mean of the samples, the middle of the diamond is the mean and the tips of this 
diamond represent the certainty of the mean. 
 
Western Blot Analysis of Tear Samples from 20 Adults  
To separate and detect the lacritin isoforms, tear samples were loaded on Any kD™ 
Mini-PROTEAN® TGX™ Precast Protein Gels (Bio-Rad), electrophoresed at 200 V, and 
transferred to nitrocellulose (Protran BA 83; Whatman, Dassel, Germany). Blots were blocked 
with PBS + 0.3% Tween 20 (PBST), incubated with anti-Lacritin N-Term (1:500 dilution in 
PBST) for 1 hour at room temperature, rinsed with PBST, and incubated for 1 hour at room 
temperature with fluorescently labeled goat anti-rabbit antibodies (1:12,500 dilution in PBS-T).  
Western blots were imaged with a LI-COR Odyssey CLx imaging system which revealed the 
presence of each lacritin isoform: cross-linked lacritin (75kDa), monomeric lacritin (25kDa), and 





Figure 4. Western Analysis of Lacritin Isoforms from 20 Adults. Lacritin isoforms from tear samples 
of both right (OD) and left (OS) eyes were detected through western blots for samples 101-120. Isoforms 
are denoted to the right with corresponding molecular weights in kDa denoted to the left: cross-linked 
lacritin (75 kDa), monomeric lacritin (25 kDa), and splice variant lacritin (15 kDa). Schirmer tear test 
values (STT) are given for each sample (mm absorbed) in their corresponding lane at the bottom of each 
western blot. 
 
Quantitation of Tear Lacritin Isoforms from 20 Adults 
To quantify the nanograms and percent lacritin isoforms, western blot images obtained 
from the LiCor Odyssey CLx imaging system were analyzed using ImageSoftwareLite. This 
produced values for each western band using relative fluorescent signals obtained at the 800nm 
wavelength (Figure 5). Relative signals of decreasing concentrations of recombinant lacritin run 
on each gel were used to generate a standard curve (Figure 5). The standard curve allowed for the 
quantitation of total lacritin and each lacritin isoform in nanograms (Figure 5), which were then 




lacritin isoform present within each sample (Figure 5). Western blots of 40 tear samples and 
recombinant lacritin showing the relative signals is in Appendix B. An example is given of the 
quantitation and a summary table of the data generated for samples 101-104 (OD and OS) (Figure 
5).     
Figure 5. Quantitation of Tear Samples 101 – 104. Lacritin isoforms from both the right (OD) and left 
(OS) eyes in each sample, as well as, recombinant lacritin standards were quantitated using relative signal 
to generate a standard curve. This was compared to total eluted protein to determine molarity, nanograms, 
and percent lacritin in each sample expressed as ng lacritin per 100ng total protein.  
 
Distribution of Total Lacritin Isoforms from 20 Adults  
To exhibit the potential for a baseline distribution of nanograms as well as percentages of 
lacritin isoforms, the obtained masses and percentages from the western blots were distributed in 
a quartile system using JMP software (Figure 6) (Figure 7). Nanograms of combined lacritin 




standard curves generated in the quantitated western blots (Appendix B). The median total 
lacritin in nanograms was 211.5 ng and the median total percent lacritin was 7.24% (Figure 6) 
(Figure 7). The 25th quartiles and 75th quartiles for total nanograms of lacritin and total percent 
lacritin were 136.5 ng, 326.25 ng, and 5.43%, 10.21%, respectively (Figure 6) (Figure 7). For 
each of the isoforms (cross-link, monomer and splice-variant) the median percentages were 




Figure 6. Distribution of Total Lacritin (ng) for Samples 101-120. The distribution of total lacritin 
(ng) (A) and the distribution of total lacritin (ng) by quartile system (B) are given. The standard deviation 
is represented to the right of the curve along with tick marks denoting the 5th and 95th percentiles of the 
curve. Additionally, the curves are divided into quartiles (25th, 50th, and 75th) as denoted by the box to the 
right of the curve. The diamond within this quartile box represents the mean of the samples; the middle of 









Figure 7.  Distribution of Percent Lacritin Isoforms and Total Percent Lacritin for Samples 101-
120. The standard deviation is represented to the right of the curves along with tick marks denoting the 5th 
and 95th percentiles of the curve. Additionally, the curves are divided into quartiles (25th, 50th, and 75th) as 
denoted by the box to the right of the curve. The diamond within this quartile box represents the mean of 
the samples, the middle of the diamond is the mean and the tips of this diamond represent the certainty of 





A multiplex western blot immunoassay that detects three isoforms of human tear lacritin 
was validated for future use in human clinical trials. Quantitation of the lacritin isoforms and 
recombinant lacritin with the LI-COR Odyssey CLx imaging system was used to calculate 
nanogram and percent total protein concentrations of three lacritin isoforms found in human 




could potentially provide diagnosis for lacritin-deficient dry eye. This immunoassay will be used 
in a LacripepTM clinical trial to determine the distribution of tear lacritin isoforms˗˗˗before and 
after topical application of a lacritin peptide on dry eye patients.  
Validation of this diagnostic western blot assay is essential in demonstrating the potential 
use of lacritin as a biomarker for dry eye associated diseases. Application of this assay on tear 
samples obtained from patients suffering from dry eye may provide a diagnostic test for future 
clinical use. N-Term and I3 antibodies demonstrated that three distinct lacritin isoforms may be 
visualized (Figure 1). All three isoforms of lacritin were then detectable in western blots using 
those anti-lacritin primary antibodies followed by fluorescent antibodies (Figure 4). Additionally, 
all three lacritin isoforms were quantifiable using the LI-COR Odyssey CLx imaging system 
which was used to calculate nanograms as well as percentages of lacritin from a recombinant 
lacritin standard curve run on the same blot (Figure 5). This allowed for the distribution of these 
isoforms using a quartile system with JMP Software (Figure 7). Thus, the application of a 
diagnostic western blot immunoassay was validated and the potential for lacritin as a diagnostic 
biomarker for dry eye was demonstrated. 
Tear film is a complex mixture of 183 extracellular proteins of which 4-5% of these 
proteins are related to of dry eye disease (Laurie et al., 2008). By placing emphasis on ocular 
proteins, protein therapeutics may be developed to treat the cause, rather than the symptoms of 
ocular diseases, like dry eye. This is particularly true when studying the roles of proteins like 
lacritin in the tear proteome. Lacritin has been shown to be deficient in varying forms of dry eye, 
most notably, Sjӧgren’s syndrome dry eye (Karnati et al., 2013). When present in sufficient 
amounts, lacritin increases basal tear secretion and has cytoprotective and mitogenic properties 




lacritin-deficient ocular disease possible and allow for the prescription of topical lacritin 
treatments. A novel therapeutic, LacripepTM, is currently being analyzed in a human clinical trial 
as an effective treatment for dry eye. 
LacripepTM utilizes a synthetic 19 amino acid derivative of lacritin as a topical 
therapeutic for a study in SS dry eye patients. After meeting exclusion and inclusion criteria, 201 
patients, as well as age-matched controls, were recruited for a clinical trial (TearSolutions, 
2017).  In a triple-blind study to identify the efficacy of differing strengths of LacripepTM, 201 
patients were divided into three groups, receiving either one of two LacripepTM ophthalmic 
solutions of differing strengths or a placebo (TearSolutions, 2017). Patients were administered 
their designated ophthalmic solution over four weeks, three times daily (TearSolutions, 2017). 
Samples from these patients and age-matched controls were then collected on Schirmer strips 
and shipped to James Madison University, where analysis of the tear samples will take place. 
The multiplex western blot immunoassay will be used to identify the distribution of percent 
lacritin isoforms in a quartile system, providing a baseline for future diagnosis of dry eye 
patients. 
 Throughout this study a multiplex western blot assay was developed for the use in human 
clinical trials to diagnose lacritin-deficient dry eye. By properly diagnosing dry eye patients 
using lacritin as a protein biomarker, a lacritin therapeutic, LacripepTM, can be administered to 
patients to treat the cause rather than the symptoms of their specific form of dry eye. Therefore, 
the validated diagnostic western blot assay will contribute to the improvement of dry eye 
diagnosis, providing many patients with relief from a disease with no previous consensus on 
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